WntResearch AB (NGM: WNT)

Market Cap	6.03M
Revenue (ttm)	n/a
Net Income (ttm)	-41.00M
Shares Out	8.66M
EPS (ttm)	-7.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,180
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	0.600 - 17.200
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 15, 2024

About WntResearch AB

WntResearch AB, a biotech company, develops therapies to prevent the metastatic process. The company develops Foxy-5, a peptide, which is in Phase II clinical trials that reduced the risk of metastasis in patients with colon cancer. It is also developing Box-5, a WNT5A antagonist for the treatment of malignant melanoma, and pancreatic and gastric cancer. The company was incorporated in 2007 and is based in Lund, Sweden.

• Industry: Other
• Founded: 2007
• Employees: 2
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: WNT